Insider and Congress filings

Gilead Sciences, Inc. (GILD)

Drug Manufacturers, listed on NASDAQ.

S&P 500Nasdaq 100350 insider transactions113 Congress tradeslast filed Nov 10, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

Insider sellingForm 4 · filed Nov 2 to Nov 6, 2026

CEO Daniel Patrick O'Day sold $25.0M from Oct 30 to Nov 5.

Four open-market sales under a 10b5‑1 plan, reported on Form 4.

Oct 30Daniel Patrick O'Day$2.8M
Nov 2Daniel Patrick O'Day$2.5M
Nov 4Daniel Patrick O'Day$18.0M
Nov 5Daniel Patrick O'Day$1.7M
Nov 6Keeley M. Cain Wettan$558K

Each bar is one Form 4 filing, as the table below lists it; the lit bars are the ones the statement sums.

19 open-market sales, all under 10b5‑1 plans.

19 of 19 under a plan

A median 1 business day from trade to filing. Form 4 is due within two.

Counted without 1 sale the table lists as filed: the same trade filed twice by joint holders.

Every filing

EarningsQ3 FY2026 · reported Oct 29, 2026

Q3 FY2026: Beat +16.4% on adjusted EPS. Revenue beat by 6.3%. Next report Feb 9, 2027.

EPS Q3 FY2026

Reported$2.55
Consensus$2.19

Revenue Q3 FY2026

Reported$8.30B
Consensus$7.81B

Beat 6

Consensus $1.29 a share on $8.30B of revenue, the analysts’ forecast.

Every quarter

Money managersEach manager’s last 13F filing

2

of the 97 fund managers GetSignal tracks list Gilead Sciences among their largest positions. Holocene Advisors held the most, $406.4M.

Every manager
Companyfrom the company's filings and listing, as of Nov 13, 2026

About Gilead Sciences, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Daniel O'Day
Employees
17,000
Listed since
Jan 22, 1992
Market value
$208.3B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$3.11
Dividend yield
1.94%

www.gilead.com

GetSignal News2 articles · newest first

GetSignal News

HeadlineSourceDate
Gilead Sciences details Phase 3 IDEAL results for Livdelzi in PBCThe results cover people with PBC treated with Livdelzi in second-line treatment, according to the company.Company releaseNov 5, 2026
Gilead Sciences to acquire oral IL-23R inhibitor HCXT-2001 from PepStarThe program is investigational, and seller PepStar Therapeutics Limited is a privately held, clinical-stage biotechnology company.Company releaseOct 22, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

Company news from every company we cover

Earnings6 reported quarters · next on Feb 9, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 29, 2026$2.55$2.19$8.3B$7.8BEPS beatRevenue beat
Q2 FY2026reported Aug 4, 2026-$6.75-$7.25$7.8B$7.4BEPS beatRevenue beat
Q1 FY2026reported May 7, 2026$2.03$1.91$7.0B$6.9BEPS beatRevenue in line
Q4 FY2025reported Feb 10, 2026$1.86$1.81$7.9B$7.7BEPS beatRevenue beat
Q3 FY2025reported Oct 30, 2025$2.47$2.13$7.8B$7.4BEPS beatRevenue beat
Q2 FY2025reported Aug 7, 2025$2.01$1.96$7.1B$7.0BEPS beatRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Earnings call briefs2 calls · newest first

Earnings call briefs

Q3 2026 call

Gilead Sciences puts 2028 Biktarvy net impact at approximately $1.5 billion

Gilead Sciences said it expects 2028 Biktarvy revenue to decline from 2027; the analysis is preliminary and subject to change.

Biktarvy Medicare price set by CMS
$2,600 per 30-day supply
Discount from Medicare channel list price
Approximate 38%
2028 Biktarvy net revenue impact outlook
Reduction of approximately $1.5 billion, preliminary and subject to change

Read the full brief

Written by GetSignal with AI from each earnings call; every brief quotes the executives' own words. Key facts are what the company said on the call, not our forecast. Not investment advice.

Earnings call briefs from every company we cover

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on GILD, newest first
FirmRatingTargetActionDate
ArgusNot stated$190Target set
JefferiesBuy$196Target set
BernsteinOutperform$175Raised from $160
UBSBuy$195Raised from $175
TD CowenBuy$175Target set
BMO CapitalOutperform$184Raised from $160
BofA SecuritiesBuy$164Raised from $162
RBC CapitalSector Perform$126Raised from $123
Truist SecuritiesBuy$158Raised from $150
HSBCBuy$175Raised from $155
BarclaysEqual Weight$145Cut from $155
Morgan StanleyOverweight$165Cut from $166
LeerinkMarket Perform$127Target set
Maxim GroupBuy$165Target set
MizuhoNot stated$170Raised from $140
ScotiabankSector Outperform$177Target set
OppenheimerNot stated$165Target set
Cantor FitzgeraldOverweight$155Raised from $135
NeedhamBuy$170Target set
BairdNot stated$145Target set
Wells FargoOverweight$165Target set
Wolfe ResearchNot stated$150Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

2 other firms rated GILD in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 13, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Mar 20, 2026

Executive pay

Daniel P. O’Day’s pay as CEO came to $28.4M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Daniel P. O’DayChairman and Chief Executive Officer$1.8M$15.2M$11.4M$28.4M
Dietmar Berger, M.D., Ph.D.Chief Medical Officer$969K$7.0M$6.0M$13.9M
Johanna MercierChief Commercial and Corporate Affairs Officer$1.2M$4.6M$3.6M$9.3M
Andrew D. DickinsonChief Financial Officer$1.1M$4.3M$3.3M$8.8M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

2,293 institutions reported Gilead Sciences shares in 13F filings for Jun 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$15.4B121,844,108+2.4%9.80%
Vanguard Capital Management LLC$10.2B81,091,734+0.5%6.52%
FMR LLC$8.4B66,870,816-7.0%5.38%
State Street Corp$7.7B61,216,552+2.3%4.93%
Capital World Investors$5.2B40,988,975-0.7%3.30%
Invesco Ltd.$5.0B39,819,151+52.8%3.20%
Vanguard Portfolio Management LLC$4.5B35,316,168+0.5%2.84%
Geode Capital Management, LLC$3.8B30,065,642+1.1%2.42%
T. Rowe Price Associates, Inc.$3.8B29,996,694+14.3%2.41%
Morgan Stanley$3.0B24,004,354+3.0%1.93%
Dodge & Cox$3.0B23,677,567-2.4%1.90%
Norges Bank$2.8B21,965,555New1.77%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings2 managers

Tracked fund managers holding GILD

ManagerValueSharesShare of book
Holocene AdvisorsQ2 2026$406.4M3,216,8920.9%
Renaissance TechnologiesFounded by Jim Simons · Q3 2026$306.3M2,054,8760.4%

2 of the 97 fund managers we track list GILD shares among the largest positions in their latest 13F. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 420 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Keeley M. Cain WettanEVP Gen Counsel, Legal & CompSold · scheduled3,399$164.11$558KNov 6, 2026filed Nov 9, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled9,810$175.17$1.7MNov 5, 2026filed Nov 6, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled102,619$175.16$18.0MNov 4, 2026filed Nov 6, 20262d
Daniel Patrick O'DayChairman & CEOSold · scheduled · 5 lines15,000$169.74$2.5MNov 2, 2026filed Nov 2, 20260d
Daniel Patrick O'DayChairman & CEOSold · scheduled15,881$175.25$2.8MOct 30, 2026filed Nov 2, 20261d
Andrew D. DickinsonChief Financial OfficerSold · scheduled3,000$156.22$469KOct 15, 2026filed Oct 16, 20261d
Johanna MercierChief Comm & Corp Aff OfficerSold · scheduled3,000$156.22$469KOct 15, 2026filed Oct 16, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled · 2 lines15,000$147.90$2.2MOct 1, 2026filed Oct 2, 20261d
Andrew D. DickinsonChief Financial OfficerSold · scheduled3,000$145.29$436KSep 15, 2026filed Sep 16, 20261d
Johanna MercierChief Comm & Corp Aff OfficerSold · scheduled · 3 lines3,000$144.22$433KSep 15, 2026filed Sep 16, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled · 3 lines15,000$148.64$2.2MSep 1, 2026filed Sep 2, 20261d
Anthony WeltersDirectorSold · scheduled · 4 lines18,000$148.62$2.7MAug 26, 2026filed Aug 27, 20261d
Jeffrey BluestoneDirectorSold · scheduled · 5 lines5,000$145.02$725KAug 20, 2026filed Aug 21, 20261d
Andrew D. DickinsonChief Financial OfficerSold · scheduled3,000$138.36$415KAug 17, 2026filed Aug 18, 20261d
Johanna MercierChief Comm & Corp Aff OfficerSold · scheduled · 2 lines28,000$137.64$3.9MAug 17, 2026filed Aug 18, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled · 3 lines15,000$130.31$2.0MAug 3, 2026filed Aug 4, 20261d
Johanna MercierChief Comm & Corp Aff OfficerSold · scheduled3,000$129.92$390KJul 15, 2026filed Jul 16, 20261d
Andrew D. DickinsonChief Financial OfficerSold · scheduled3,000$129.93$390KJul 15, 2026filed Jul 16, 20261d
Daniel Patrick O'DayChairman & CEOSold · scheduled · 2 lines15,000$126.29$1.9MJul 1, 2026filed Jul 2, 20261d
Andrew D. DickinsonChief Financial OfficerSold · scheduled3,000$125.40$376KJun 15, 2026filed Jun 16, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Daniel Patrick O'DayChairman & CEOOption exercise9,810Nov 5, 2026
Daniel Patrick O'DayChairman & CEOOption exercise102,619Nov 4, 2026
Daniel Patrick O'DayChairman & CEOOption exercise15,881Oct 30, 2026
Erin BurkhartSVP, ControllershipTax withholding768Sep 22, 2026
Erin BurkhartSVP, ControllershipOption exercise2,223Sep 22, 2026
Daniel Patrick O'DayChairman & CEOTax withholding4,230Sep 10, 2026
Daniel Patrick O'DayChairman & CEOOption exercise8,780Sep 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & CompTax withholding285Sep 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & CompOption exercise590Sep 10, 2026
Johanna MercierChief Comm & Corp Aff OfficerTax withholding1,347Sep 10, 2026
Johanna MercierChief Comm & Corp Aff OfficerOption exercise2,797Sep 10, 2026
Dietmar BergerChief Medical OfficerTax withholding263Sep 10, 2026
Dietmar BergerChief Medical OfficerOption exercise533Sep 10, 2026
Andrew D. DickinsonChief Financial OfficerTax withholding1,347Sep 10, 2026
Andrew D. DickinsonChief Financial OfficerOption exercise2,797Sep 10, 2026
Anthony WeltersDirectorOption exercise18,000Aug 26, 2026
Jeffrey BluestoneDirectorOption exercise9,665Aug 20, 2026
Johanna MercierChief Comm & Corp Aff OfficerOption exercise25,000Aug 17, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & CompTax withholding2,908Aug 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & CompOption exercise6,002Aug 10, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act20 disclosures of 113 on record · median 28d of the 45 allowed

Congress trades in GILD

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Ro KhannaStockSale$1,001 - $15,000+26.2% since the saleEstimated exit price $133.06, close on Mon Aug 10Current price $167.95, close on Thu Nov 12Aug 10, 2026Sep 4, 202625d
Ro KhannaStockSale$1,001 - $15,000+23.2% since the saleEstimated exit price $136.36, close on Tue Jul 7Current price $167.95, close on Thu Nov 12Jul 7, 2026Aug 7, 202631d
Ro KhannaStockPurchase$1,001 - $15,000+26.1% since the tradeEstimated entry price $133.21, close on Mon Jul 20Current price $167.95, close on Thu Nov 12Jul 20, 2026Aug 7, 202618d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+25.1% since the tradeEstimated entry price $134.25, close on Fri Mar 27Current price $167.95, close on Thu Nov 12Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockSale$15,001 - $50,000+32.0% since the saleEstimated exit price $127.23, close on Tue Jun 16Current price $167.95, close on Thu Nov 12Jun 16, 2026Jul 6, 202620d
Jared MoskowitzStockPurchase$1,001 - $15,000+23.2% since the tradeEstimated entry price $136.30, close on Wed May 6Current price $167.95, close on Thu Nov 12May 6, 2026Jun 19, 202644d
Ro KhannaStockPurchase$15,001 - $50,000+29.6% since the tradeEstimated entry price $129.58, close on Fri May 15Current price $167.95, close on Thu Nov 12May 15, 2026Jun 9, 202625d
Ro KhannaStockSale$15,001 - $50,000+20.8% since the saleEstimated exit price $139.03, close on Mon Apr 13Current price $167.95, close on Thu Nov 12Apr 13, 2026May 11, 202628d
Josh GottheimerJointStockPurchase$1,001 - $15,000+19.1% since the tradeEstimated entry price $140.97, close on Tue Jan 27Current price $167.95, close on Thu Nov 12Jan 27, 2026Feb 26, 202630d
Ro KhannaStockPurchase$15,001 - $50,000+20.4% since the tradeEstimated entry price $139.55, close on Thu Jan 29Current price $167.95, close on Thu Nov 12Jan 29, 2026Feb 6, 20268d
Val T. HoyleSpouseStockSale$1,001 - $15,000+46.8% since the saleEstimated exit price $114.40, close on Tue Sep 23, 2025Current price $167.95, close on Thu Nov 12Sep 23, 2025Oct 10, 202517d
Val T. HoyleSpouseStockPurchase$1,001 - $15,000+90.7% since the tradeEstimated entry price $88.08, close on Tue Oct 29, 2024Current price $167.95, close on Thu Nov 12Oct 29, 2024Sep 12, 2025318d
Jefferson ShreveStockSale$15,001 - $50,000+61.8% since the saleEstimated exit price $103.82, close on Mon May 12, 2025Current price $167.95, close on Thu Nov 12May 12, 2025Jun 22, 202541d
Marjorie Taylor GreeneStockPurchase$1,001 - $15,000+49.3% since the tradeEstimated entry price $112.46, close on Fri Jun 6, 2025Current price $167.95, close on Thu Nov 12Jun 6, 2025Jun 18, 202512d
Josh GottheimerJointStockSale$1,001 - $15,000+70.7% since the saleEstimated exit price $98.38, close on Wed May 14, 2025Current price $167.95, close on Thu Nov 12May 14, 2025Jun 11, 202528d
John BoozmanJointStockSale (Full)$1,001 - $15,000+60.1% since the saleEstimated exit price $104.88, close on Wed Apr 16, 2025Current price $167.95, close on Thu Nov 12Apr 16, 2025May 14, 202528d
Marjorie Taylor GreeneStockPurchase$1,001 - $15,000+63.4% since the tradeEstimated entry price $102.81, close on Mon May 5, 2025Current price $167.95, close on Thu Nov 12May 5, 2025May 6, 20251d
Jefferson ShreveStockPurchase$15,001 - $50,000+49.9% since the tradeEstimated entry price $112.05, close on Mon Mar 31, 2025Current price $167.95, close on Thu Nov 12Mar 31, 2025Apr 11, 202511d
Carol D. MillerStockPurchase$1,001 - $15,000+43.3% since the tradeEstimated entry price $117.21, close on Mon Mar 10, 2025Current price $167.95, close on Thu Nov 12Mar 10, 2025Apr 11, 202532d
Josh GottheimerJointStockPurchase$1,001 - $15,000+43.0% since the tradeEstimated entry price $117.41, close on Fri Mar 7, 2025Current price $167.95, close on Thu Nov 12Mar 7, 2025Apr 10, 202534d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in GILD filterable by party, chamber, type and account.

STOCK Act15 members · estimate, as of Nov 12, 2026

Members of Congress reporting a position

15 members report a position of $1,000 or more (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
J. French HillRepublican · House$100,001 - $250,0000.6%
Jacky RosenDemocrat · Senate$50,001 - $100,0001.0%
Deborah K. RossDemocrat · House$15,001 - $50,0003.3%
Gilbert Ray Cisneros, Jr.Democrat · House$15,001 - $50,0000.1%
Robert BresnahanRepublican · House$15,001 - $50,0000.3%
Lucy McBathDemocrat · House$15,001 - $50,0000.5%
Jared MoskowitzDemocrat · House$15,001 - $50,0000.4%
Angus S. King Jr.Independent · Senate$1,001 - $15,0000.3%
Rand PaulRepublican · Senate$1,001 - $15,00057.1%
Shelley Moore CapitoRepublican · Senate$1,001 - $15,0000.6%
Carol D. MillerRepublican · House$1,001 - $15,0000.5%
Julie JohnsonDemocrat · House$1,001 - $15,0000.1%
Robert B. AderholtRepublican · House$1,001 - $15,0001.3%
Josh GottheimerDemocrat · House$1,001 - $15,000<0.1%
John BoozmanRepublican · Senate$1,001 - $15,0000.1%

A further member reports a position estimated under $1,000; that member is not listed.

The largest estimated position is in the $100,001 - $250,000 band. Estimate, as of Nov 12, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 13, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on GILD show and how current they are.

Are insiders buying or selling GILD?

Across the 20 most recent open-market filings shown here, 0 were purchases and 20 were sales. 20 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded GILD?

Ro Khanna, Alan Armstrong, Jared Moskowitz, Josh Gottheimer, Val T. Hoyle, Jefferson Shreve and others disclosed GILD transactions in the filings shown here.

Which members of Congress hold GILD?

15 members of Congress report a position of $1,000 or more in GILD in the estimate we hold as of Nov 12, 2026. The two largest estimated positions belong to J. French Hill and Jacky Rosen; Deborah K. Ross holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is GILD in the S&P 500 or the Nasdaq 100?

Gilead Sciences, Inc. is a current member of the S&P 500 and Nasdaq 100, per the membership list we hold as of Nov 13, 2026. Current members of either index get a page here whatever their filing history.

How quickly are GILD trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track